Jennison Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-338,509
Closed -$18M 685
2017
Q3
$18M Sell
338,509
-131,523
-28% -$7.79M 0.02% 417
2017
Q2
$29.2M Sell
470,032
-30,258
-6% -$1.82M 0.03% 345
2017
Q1
$33.9M Hold
500,290
0.04% 335
2016
Q4
$35.2M Buy
500,290
+1,844
+0.4% +$131K 0.04% 321
2016
Q3
$35.4M Buy
498,446
+405
+0.1% +$25.9K 0.04% 329
2016
Q2
$24.4M Sell
498,041
-86,706
-15% -$5.61M 0.03% 380
2016
Q1
$37M Sell
584,747
-170,641
-23% -$11.2M 0.04% 330
2015
Q4
$84.7M Buy
755,388
+9,724
+1% +$972K 0.08% 206
2015
Q3
$71.8M Buy
745,664
+4,412
+0.6% +$505K 0.07% 234
2015
Q2
$75.9M Buy
741,252
+5,638
+0.8% +$438K 0.07% 257
2015
Q1
$45.7M Buy
735,614
+1,912
+0.3% +$106K 0.04% 338
2014
Q4
$32.2M Sell
733,702
-24,864
-3% -$1.14M 0.03% 384
2014
Q3
$42.9M Buy
758,566
+540,405
+248% +$27.2M 0.04% 356
2014
Q2
$9.79M Sell
218,161
-65,059
-23% -$2.68M 0.01% 480
2014
Q1
$13.8M Buy
+283,220
New +$14.6M 0.01% 473

Other funds holding RARE

Jennison Associates's RARE Position: Q4 2017 in Review

Jennison Associates sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2017, closing a stake of 338,509 shares — an estimated $18M sold.

Jennison Associates first reported a position in RARE in Q1 2014 and held it in 15 quarters. The position peaked at $84.7M in Q4 2015. 163 funds tracked by Wall St. Rank hold RARE as of Q4 2017.

  • Jennison Associates reported no remaining Ultragenyx Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • Jennison Associates sold 338,509 Ultragenyx Pharmaceutical shares in Q4 2017, an estimated $18M.
  • Jennison Associates first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 15 quarters.
  • Jennison Associates's Ultragenyx Pharmaceutical position peaked at $84.7M in Q4 2015.
  • 163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2017.

Based on Jennison Associates's 13F filing for Q4 2017, filed 25 Jan 2018.